Table 1 Comparison of two groups at baseline
| Â | Treatment group | Control group | p-value |
|---|---|---|---|
Sex** (M/F) | 8/7 | 5/10 | 0.231 |
Age* (years) | 51.2 ± 7.8 | 51.7 ± 9.9 | 0.677 |
Diabetes duration* (months) | 60.0 ± 46.3 | 51.1 ± 39.6 | 0.618 |
BMI* (kg/m2) | 29.2 ± 5.7 | 27.3 ± 5 | 0.580 |
PI* (%) | 80.5 ± 13.1 | 79.3 ± 19.3 | 0.395 |
GBI* (%) | 39.5 ± 18.9 | 37.2 ± 17.4 | 0.787 |
PD* (mm) | 3.0 ± 0.4 | 3.1 ± 0.6 | 0.344 |
% sites˂4 mm | 68.7 | 71.7 |  |
% sites 4-6Â mm | 31.0 | 27.3 | Â |
% sites ˃6 mm | 0.3 | 0.9 |  |
CAL* (mm) | 3.4 ± 0.5 | 3.3 ± 0.6 | 0.575 |
% sites Ë‚4Â mm | 57.0 | 64.4 | Â |
% sites 4-6Â mm | 41.7 | 33.6 | Â |
% sites ˃6 mm | 1.3 | 2.0 |  |
HbA1c* (%) | 9.7 ± 1.6 | 8.9 ± 0.9 | 0.394 |
Methods used to control hyperglycemia** | |||
 Diet | 15 | 15 |  |
 OAD | 13 | 7 | 0.025 |
 Insulin | 10 | 11 | 0.500 |
 OAD + insulin | 8 | 3 | 0.308 |
Complications** | |||
 Neuropathy | 6 | 6 | 0.645 |
 Néphropathy | 1 | 1 | 0.759 |
 Rétinopathy | 2 | 0 | 0.500 |
 Diabetic foot | 0 | 1 | 0.241 |